Analysts Set Medicus Pharma Ltd (NASDAQ:MDCX) Target Price at $23.50

Medicus Pharma Ltd (NASDAQ:MDCX) has received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and two have given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $23.50.

Several analysts have recently commented on the stock. D. Boral Capital reiterated a “buy” rating and issued a $27.00 target price on shares of Medicus Pharma in a report on Wednesday, October 29th. Zacks Research upgraded shares of Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC bought a new stake in shares of Medicus Pharma during the 1st quarter worth $4,710,000. Guyasuta Investment Advisors Inc. bought a new stake in Medicus Pharma in the second quarter worth about $230,000. Private Advisor Group LLC purchased a new position in Medicus Pharma in the first quarter valued at about $211,000. SeaCrest Wealth Management LLC purchased a new position in Medicus Pharma in the second quarter valued at about $139,000. Finally, May Hill Capital LLC purchased a new position in Medicus Pharma in the second quarter valued at about $107,000.

Medicus Pharma Stock Down 1.2%

MDCX stock opened at $2.39 on Thursday. Medicus Pharma has a twelve month low of $1.79 and a twelve month high of $8.94. The stock’s 50 day moving average is $2.38 and its 200-day moving average is $3.04. The firm has a market capitalization of $42.59 million and a PE ratio of -1.78.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). On average, equities research analysts anticipate that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.